Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Passes Below 200 Day Moving Average – Here’s Why

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $8.32 and traded as low as $5.84. Enanta Pharmaceuticals shares last traded at $5.88, with a volume of 166,938 shares traded.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. JMP Securities reiterated a “market outperform” rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.25.

Enanta Pharmaceuticals Stock Performance

The company has a market capitalization of $125.01 million, a price-to-earnings ratio of -1.18 and a beta of 0.48. The business has a 50 day moving average price of $6.38 and a 200-day moving average price of $8.30.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. As a group, equities analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly bought 45,000 shares of Enanta Pharmaceuticals stock in a transaction dated Wednesday, February 12th. The stock was bought at an average cost of $5.69 per share, with a total value of $256,050.00. Following the completion of the acquisition, the chief executive officer now directly owns 846,638 shares in the company, valued at approximately $4,817,370.22. The trade was a 5.61 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 13.89% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ENTA. China Universal Asset Management Co. Ltd. bought a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth $26,000. Tower Research Capital LLC TRC increased its holdings in Enanta Pharmaceuticals by 46.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock worth $41,000 after buying an additional 2,274 shares during the last quarter. Intech Investment Management LLC bought a new stake in Enanta Pharmaceuticals in the fourth quarter worth about $58,000. Squarepoint Ops LLC purchased a new position in Enanta Pharmaceuticals in the fourth quarter valued at about $66,000. Finally, Velan Capital Investment Management LP bought a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at approximately $75,000. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.